16 results about "Diphenhydramine" patented technology

To provide an ophthalmic product in which an ophthalmic composition is filled in a container in which a pressing deformation part is formed by using an elastic material, and although the ophthalmic composition contains chlorpheniramine, diphenhydramine or a salt thereof, adsorption of these components is suppressed.SOLUTION: An ophthalmic product comprising an ophthalmic composition and a container filled with the ophthalmic composition, wherein the container comprises a container body having a discharge port and a press-deforming part, and a cap, and the press-deforming part is formed using an elastic material, (A) one or more selected from the group consisting of chlorpheniramine, diphenhydramine, and pharmaceutically acceptable salts thereof, and (B) one or more selected from the group consisting of an amino acid and a salt thereof, glycyrrhizic acid and a salt thereof, a mucopolysaccharide and a salt thereof, trometamol and a salt thereof, ethylenediaminetetraacetic acid and a salt thereof, and a vitamin and a derivative thereof.SELECTED DRAWING: Figure 1

The present invention aims to provide a novel formulation that improves the emulsification stability of an emulsifying composition containing ufenamate. [Solution] When an emulsifying composition containing ufenamate is blended with at least one selected from the group consisting of diphenhydramine, allantoin, and its derivatives, the emulsifying stability of the emulsifying composition is improved.

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

To provide a topical scalp composition that can suppress scalp odor while reducing scalp itching.SOLUTION: Provided is a topical scalp composition comprising (A) a heparin-like substance and (B) diphenhydramine and / or a salt thereof, the composition having a viscosity of 140 Pa s or less.SELECTED DRAWING: None

The invention relates to the technical field of traditional Chinese medicine external preparations, in particular to a bone strengthening emplastrum and a preparation method thereof. The invention relates to a bone strengthening emplastrum, which comprises the following medicines: safflower, belladonna liquid extract, corydalis tuber, menthol, divaricate saposhnikovia root, teasel root, cicada slough, suberect spatholobus stem, clematis root, camphor, monkshood, fleece-flower root, borneol, methyl salicylate, diphenhydramine and mature vinegar. The matrix comprises rubber, zinc oxide, rosin, vaseline, wool fat and gasoline; at least one of sodium polyacrylate, sodium alginate, xanthan gum, a hydrophobic modified product of the xanthan gum, chitosan, hydroxypropyl methyl cellulose and polyvinylpyrrolidone is added into the bone strengthening emplastrum. By adding the substances, the stability of the mucilage can be effectively improved, so that separation and layering of the mucilage are avoided, the technical problem of non-ideal product quality caused by poor stability of the mucilage of the bone strengthening rubber emplastrum and the preparation method of the bone strengthening rubber emplastrum can be solved, and the product quality and the application prospect are improved.

The invention belongs to the technical field of chemical component detection, and particularly relates to a method for detecting residues of NDMA, NMBA, NDEA, NDIPA and NDBA in tea diphenhydramine, which comprises the following steps: (1) preparing a tea diphenhydramine test solution; and (2) determining the tea diphenhydramine test solution by using a liquid chromatography-mass spectrometry method, and liquid chromatography conditions are as follows: a chromatographic column takes phenyl-hexyl bonded silica gel as a filler, an aqueous solution containing trifluoroacetic acid and ammonium formate as a mobile phase A, and a methanol-acetonitrile mixed solution containing trifluoroacetic acid as a mobile phase B, gradient elution is performed, and the content of the tea diphenhydramine is determined. The residual contents of NDMA, NMBA, NDEA, NDIPA and NDBA in a tea diphenhydramine test sample are calculated by adopting an external standard method. The method provided by the invention plays an important role in formulating and improving quality standards of tea diphenhydramine bulk drugs and preparations.

The invention belongs to the technical field of pharmacy, and particularly relates to a diphenhydramine citrate ibuprofen double-layer tablet and a preparation method thereof. The diphenhydramine citrate double-layer tablet comprises a diphenhydramine citrate layer and an ibuprofen layer, wherein the diphenhydramine citrate layer comprises 17.5% of diphenhydramine citrate, 30%-70% of a filling agent, 1%-5% of a flow aid, 3%-10% of a disintegrating agent, 5%-15% of an adhesive, 1%-5% of a lubricating agent and 0.1%-0.5% of a coloring agent; the ibuprofen layer comprises 62.9% of ibuprofen, 20%-50% of a filling agent, 0.1%-1% of a flow aid, 2%-10% of a disintegrating agent, 5%-15% of an adhesive, 0.05%-0.5% of a solubilizer and 0.1%-1% of a lubricant; the coating layer is 2%-4% of a gastric-soluble film coating premix; the double-layer sheet provided by the invention has better stability.

Compositions and formulations containing diphenhydramine and lactoferrin are described for preventing or treating infection with SARS-CoV-related betacoronavirus. Methods of using the compositions and formulations are also described. The methods include administering the compositions or formulations containing diphenhydramine and lactoferrin to a patient at risk of infection with SARS-CoV-related betacoronavirus or suffering from a SARS-CoV-related betacoronavirus-associated disease.

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

This disclosure relates to compositions for treating skin conditions and improving skin health. In particular, the disclosure relates to compositions formulated as an absorbent article to be topically applied to skin, the absorbent article comprising an analgesic agent, antihistamine agent and / or a corticosteroid.

The invention belongs to the technical field of biomedical materials, and provides a spraying type anti-adhesion Janus heterogeneous hydrogel film used after cholecystectomy and a preparation method of the spraying type anti-adhesion Janus heterogeneous hydrogel film. The system is prepared from a tube A cationic sulfobetaine-quaternized chitosan (QCS-SB) solution and a tube B cationic sulfobetaine-quaternized chitosan (QCS-SB) solution, wherein the QCS-SB solution contains temperature-sensitive lipidosome for packaging diphenhydramine and blood coagulation peptide; and a cartridge B anionic polycarboxy betaine (PCB-AA) solution, wherein the cartridge B anionic polycarboxy betaine (PCB-AA) solution contains calcium alginate microspheres loaded with a cholic acid adsorbent. In the operation, after the gel is synchronously sprayed to an irregular wound surface through a double-barrel spray gun, a double-layer hydrogel film is rapidly formed through electrostatic self-assembly, wet-state strong adhesion and body temperature triggered drug release are achieved on the cation function side, and a super-lubricating surface is constructed on the anion function side and actively captures bile acid. The material has the functions of physical barrier, chemical adsorption and pharmacological intervention, the postoperative adhesion rate and the allergy occurrence rate can be remarkably reduced, and an intelligent, accurate and degradable barrier solution is provided for general surgery operations.

The invention discloses a process for removing specific impurities of diphenhydramine citrate. The identification is as follows: a graph is a related substance (HPLC) graph of a diphenhydramine citrate crude product, and the impurity is named as an impurity I when Rt is equal to 15.567 min; the impurity removal method comprises the following steps: dissolving a diphenhydramine citrate crude product in a solvent, heating and dissolving, cooling the system to 40-55 DEG C, growing crystals for more than 3 hours, cooling to 0-30 DEG C, crystallizing for 2-3 hours, and filtering to obtain a diphenhydramine citrate fine product; wherein the mass volume ratio of the crude product to the solvent is 1g: (8-12) ml, and the solvent is 95% ethanol. The impurity I is disclosed, identified and confirmed for the first time, and a basis is provided for setting an impurity limit. The diphenhydramine citrate is refined by adopting a crystal growing method, the refining effect is good, the removal rate of impurities I and other impurities is high, the operation is simple, and the method is particularly suitable for industrial production.

The present invention provides a semi-solid composition comprising a gel component in an amount sufficient to provide a gel product with binding force, an antihistamine composition comprising an antihistamine agent, and a complexing agent wherein the complexing agent is capable of interacting with the antihistamine agent and forming an antihistamine complex. In one embodiment, the antihistamine agent includes diphenhydramine, cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, azelastine, bilastine, rupatadine, or a derivative, a salt, or a combination thereof.

To provide a minoxidil-containing composition for external use which suppresses discoloration of a preparation with time in a minoxidil-containing composition for external use obtained by blending at least one active ingredient selected from the group consisting of glycyrrhetinic acid and / or a salt thereof, a pantothenyl ethyl ether, panthenol, hinokitiol and diphenhydramine and / or a salt thereof.SOLUTION: There is provided a composition for external use which suppresses discoloration of a preparation with time by using a specific polyhydric alcohol, that is, there is provided a composition for external use which comprises: at least one active ingredient selected from the group consisting of minoxidil, glycyrrhetinic acid and / or a salt thereof, a pantothenyl ethyl ether, panthenol, hinokitiol and diphenhydramine and / or a salt thereof; propylene glycol; and an acid.SELECTED DRAWING: None

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.

The drug "Antigrippin R" contains ascorbic acid, rutin, diphenhydramine, calcium gluconate, rimantadine and auxiliary substances in the following ratio of components, g per one tablet weighing 0.5-0.55 g: ascorbic acid 0.05-0.3 calcium gluconate - 0.05-0.1 diphenhydramine - 0.01 -0.02 rutin - 0.01-0.02 rimantadine - 0.025-0.1 auxiliary substances to obtain a tablet. Starch, calcium stearate, talc are used as auxiliary substances.